Navigation Links
Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
Date:12/10/2012

RIDGEFIELD, Conn., Dec. 10, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.  In this study, higher rates of objective response (primary endpoint) and a trend for longer median event free survival (EFS) (a secondary endpoint) were observed in patients treated with volasertib in combination with low-dose cytarabine (LDAC) compared to patients treated with LDAC alone. Presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, Ga., these results support the initiation of a Phase III study of volasertib in combination with LDAC expected to start in early 2013. 

AML is one of the most common types of leukemia in adults.2  A common treatment approach is intensive chemotherapy to induce disease remission, followed by consolidation/maintenance chemotherapy.3,4  However, many patients over 65 years of age – whose prognosis is typically poor5 – are ineligible for this approach, which involves large doses of chemotherapy over short periods of time.3,4 

The open-label study enrolled 87 adult patients randomly assigned to receive either volasertib in combination with LDAC (n=42) or LDAC alone (n=45).   The primary endpoint was objective response (complete remission [CR] or CR with incomplete blood count recovery [CRi]).  Objective responses were observed in 31 percent of patients (13 of 42 patients) treated with the combination of volasertib plus LDAC compared with 13.3 percent of the patients (6 of 45 patients) treated with LDAC alone (odds ratio: 2.91; p = 0.0523).  The median (range) time to remission was 71 (2
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Announces Equine Research Awards
2. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
3. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
4. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
10. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
11. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis ... affordable laser tattoo removal experience with the advanced Astanza Duality laser ... high quality cosmetic services with cutting edge medical technology and offering ... California has seen a dramatic increase in the presence ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... Ultra Clean Holdings, Inc. (Nasdaq: UCTT ), a ... capital equipment, flat panel, medical, energy and research industries will ... October 24, 2011 after markets close. The Company ... results and management,s outlook at 1:45 pm PDT on Monday, ...
... The medical education landscape has changed dramatically ... pressures have reshaped approaches to Continuing Medical Education ... right staffing, investment, and delivery platforms to provide ... To help inform medical education leaders on ...
Cached Medicine Technology:Study Highlights Emerging Approaches to Medical Education in the Pharmaceutical Sector 2
(Date:7/9/2014)... The liver is one of the most important organs ... that we utilize our food properly this is ... removed from our organism this is its detoxification ... and unhealthy food all damage the liver. The resulting ... deposits, cirrhoses, and life-threatening liver failure. According to the ...
(Date:7/9/2014)... studies linking older age with kidney and heart disease ... donation among older adults. However, in the first study ... Perelman School of Medicine at the University of Pennsylvania ... enjoy similar life expectancy and cardiovascular health as very ... In light of the ever increasing organ transplant waitlists, ...
(Date:7/9/2014)... has risen dramatically in Western societies. One frequently cited ... and have fewer infections than previous generations, thereby delaying ... researchers at Sahlgrenska Academy, University of Gothenburg, monitored children ... the immune system in relation to allergic disease. All ... Vstra Gtaland Region, half of them on farms that ...
(Date:7/8/2014)... awarded up to $15 million by the Defense Advanced ... aiming to help brain-injured people restore lost memory functions. ... psychology and physics will collaborate to create, surgically implant, ... Memory is the process in which neurons in certain ... retrieve it. Certain types of illnesses and injuries disrupt ...
(Date:7/8/2014)... found to be three times higher when auditors were ... auditors present, according to a study in a major ... "Quantification of the Hawthorne effect in hand hygiene compliance ... study," published today on-line in the BMJ Quality ... Srigley, who did the study as part of her ...
Breaking Medicine News(10 mins):Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3
... Schools in the ... Country, ... in association with the School Nutrition,Association and the President,s Council on Physical ... as one,of the 25 healthiest schools in the nation. The recognition is ...
... LAKE CITY, Dec. 11 Amedica Corporation, an,orthopedic ... today that the U.S. Food and Drug Administration,has ... Valeo(TM),ceramic VBR spinal implant., The Valeo VBR ... aid in surgical correction and stabilization of the ...
... red meat and processed meat you eat, the higher the ... hamburger or a small pork chop eaten daily could put ... government health researchers report. , The more red meat ... researchers from the National Cancer Institute concluded. , "Red ...
... Panomics Inc., a,developer of innovative technologies ... the exclusive provider of QuantiGene(R) and,QuantiGene Plex(R) ... today that they have been awarded Frost ... Entrepreneurial Company of the Year,Award. Frost & ...
... YORK, Dec. 10 The holiday season is a ... Combine high-calorie,goodies with the cold winter weather, and December ... Fitness Operations VP at 24 Hour Fitness health,clubs, says ... help stave,off extra "holiday" pounds., Listen to this ...
... REDWOOD CITY, Calif., Dec. 10 Cardica, Inc.,(Nasdaq: ... of the over-allotment,option granted to the underwriters of ... their option to purchase,481,170 shares of common stock ... share., William Blair & Company, L.L.C. acted ...
Cached Medicine News:Health News:Local School Wins National got milk?(R) Healthiest Student Bodies Contest 2Health News:Local School Wins National got milk?(R) Healthiest Student Bodies Contest 3Health News:Amedica Receives FDA Special 510(k) Clearance for its Valeo(TM) Ceramic Spinal Implant 2Health News:High Meat Consumption Linked to Heightened Cancer Risk 2Health News:High Meat Consumption Linked to Heightened Cancer Risk 3Health News:High Meat Consumption Linked to Heightened Cancer Risk 4Health News:Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award 2Health News:Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award 3Health News:Cardica Announces Exercise of Over-Allotment Option 2Health News:Cardica Announces Exercise of Over-Allotment Option 3
... 450,000 people in,the United States die ... a defibrillation shock,quickly during an episode ... that passes, the chance of,survival decreases ... Association,and JCAHO recommend that AEDs be ...
... female urinary stress incontinence (SUI) with a ... (BioArc™ SP) or a transobturator (BioArc™ TO) ... system combining synthetic and biologic materials. It ... The BioArc utilizes a polypropylene mesh for ...
... technology marries with the well-researched ... sling, for exceptional resultsby design. ... and host, reduces the potential ... or erosion and provides secure ...
Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support...
Medicine Products: